This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of treating a subject suffering from a ~~disease~~ **clinical condition** associated with a herpes virus infection **selected from the group consisting of encephalitis, pharyngitis, gingivostomatitis, herpetic hepatitis, erythema multiforme, mononucleosis, Burkitt's lymphoma, primary effusion lymphomas, multiple myeloma, angioimmunoblastic lymphadenopathy, Castleman's disease, post-transplantation lymphoproliferative disease, Hodgkin's disease, T-cell lymphomas, oral hairy leukoplakia, lymphoproliferative disease, lymphoepithelial carcinoma, body-cavity-based lymphoma or B-cell lymphomas, non-keratinising carcinoma, squamous cell nasopharyngeal carcinoma, kidney transplant associated epithelial tumors, malignant mesothelioma, angiosarcoma, Kaposi's sarcoma, angiolymphoid hyperplasia, prostatic neoplasm, cervical cancer, neoplasms of the vulva, retinoblastoma, Li-Fraumeni syndrome, Gardner's syndrome, Werner's syndrome, nervoid basal cell carcinoma syndrome, neurofibromatosis type 1, polyneuropathies, motor neuropathies, sensory neuronopathies, polyradiculoneuropathies, autonomic neuropathies, focal or multifocal cranial neuropathies, radiculopathies, plexopathies typically resulting from tumor infiltration, or a combination thereof, said method** comprising: administering to the subject a therapeutically effective amount of a peptide exhibiting mammalian alpha-1 antitrypsin (AAT) or AAT-like activity.

2. (Currently Amended) The method of claim 1 in which said ~~disease~~ **clinical condition** is ~~malaise, fever, chills, rhinitis, diarrhea, atopic eczema,~~ encephalitis, ~~keratoconjunctivitis,~~ pharyngitis, gingivostomatitis, herpetic hepatitis, ~~recurrent orofacial mucocutaneous lesions or herpes labialis, chicken pox skin sores,~~ erythema multiforme, ~~idiopathic burning mouth, aphthous ulceration, Behcet's syndrome,~~ or **a combination** ~~combinations~~ thereof.

3. (Currently Amended) The method of claim 1 in which said ~~disease~~ **clinical condition** is mononucleosis, Burkitt's lymphoma, primary effusion lymphomas, multiple myeloma, angioimmunoblastic lymphadenopathy, Castleman's disease, ~~acquired immune deficiency syndrome (AIDS)-related lymphoma,~~ post-transplantation lymphoproliferative disease, Hodgkin's disease, T-cell lymphomas, oral hairy leukoplakia, lymphoproliferative

disease, lymphoepithelial carcinoma, body-cavity-based lymphoma or B-cell lymphomas, non-keratinising carcinoma, squamous cell nasopharyngeal carcinoma, kidney transplant-associated epithelial tumors, malignant mesothelioma, angiosarcoma, Kaposi's sarcoma, angiolymphoid hyperplasia, prostatic neoplasm, cervical cancer, neoplasms of the vulva, retinoblastoma, Li-Fraumeni syndrome, Gardner's syndrome, Werner's syndrome, nervoid basal cell carcinoma syndrome, neurofibromatosis type 1, or **a combination** ~~combinations~~ thereof.

4. (Currently Amended) The method of claim 1 in which said ~~disease~~ **clinical condition** is polyneuropathy, motor neuropathy, sensory neuronopathy, polyradiculoneuropathy, autonomic neuropathy, focal or multi focal cranial neuropathy, radiculopathy, plexopathy resulting from tumor infiltration, or ~~combinations~~ **a combination** thereof.

5. (Previously Presented) The method of claim 1 in which the peptide comprises AAT.

6. (Original) The method of claim 5 in which the AAT is substantially purified from a wild type, mutant, or transgenic mammalian source.

7. (Original) The method of claim 5 in which the AAT is isolated from a culture of wild type, mutant, or transformed cells.

8. (Original) The method of claim 1 in which the herpes virus comprises a virus selected from the group consisting of herpes simplex virus type I (HSV-1), herpes simplex virus type II (HSV-2), cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella zoster virus (VZV), herpes zoster virus, human herpes virus type V (HHV-5), human herpes virus type VI (HHV-6), human herpes virus type VIII (HHV-8), and combinations thereof.

9. (Cancelled).

10. (Withdrawn–Previously Presented) The method of claim 1 in which the peptide is of the general formula: N_T–X_1–X_2–X_3–X_4–X_5–C_T or a physiologically acceptable salt thereof, in which N_T comprises an amino acid residue positioned at the peptide's N-terminal end, including C, an acetyl group, or a succinyl group, provided that N_T can also be absent; X_1 comprises an amino acid residue, including F or A; X_2 comprises an amino acid residue, including C, V, L, M, I, A, C, or S; X_3 comprises an amino acid residue, including F, A, V, M, L, I, Y, or C; X_4 comprises an amino acid residue, including L, A, F, I, V, M, C, G, or S; X_5

comprises an amino acid residue, including M, A, I, L, V, F, or G; and C_T comprises an amino acid residue positioned at the peptide's C-terminal end, including C, an amide group, a substituted amide group, or an ester group, provided that C_T can also be absent, and in which the amino acid residue can be either an L- or a D-stereoisomeric configuration.

11. (Withdrawn–Previously Presented) The method of claim 1 in which the therapeutically effective amount of the peptide exhibiting mammalian alpha-1-antitrypsin (AAT) or AAT-like activity is in the range of about 1 mg per kg to about 100 mg per kg of body weight of the mammalian subject.

12. (Original) The method of claim 1 in which the therapeutically effective amount of the substance is administered systemically or topically.

13-41. (Cancelled)